Achaogen Stock

Achaogen CapEx/D&A

Delisted

CapEx to Depreciation Ratio of Achaogen (AKAOQ) as of Aug 16, 2026.

CapEx/D&A

0.00

Last updated:

CapEx to Depreciation Ratio of Achaogen is 2026 0.00 . CapEx to Depreciation Ratio of Achaogen was 2025 0.00 . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Achaogen Stock analysis

What does Achaogen do? Achaogen Inc is an innovative biotechnology company specializing in the development of antibiotics for the treatment of life-threatening infectious diseases. The company's business model is based on research and development of new antibiotics, aiming to improve medical care for patients with infections. Achaogen was founded in 2002 by a team of researchers and professionals in the biotechnology industry and has developed several products for the treatment of diseases such as pneumonia, urinary tract infections, and bloodstream infections. The company's main divisions include Plazomicin, Zemdri, and C-Scape, which are antibiotics targeting different types of infections. Achaogen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Achaogen stock

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Achaogen since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Achaogen with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

Cash Flow — Achaogen

All Key Metrics — Achaogen